ACE and glioblastoma: In 2017, Levin et al. suggested adding an ARB or ACE inhibitor to bevacizumab based on their retrospective glioblastoma study showing the overall survival of ~25 months in those receiving low dose bevacizumab plus an ARB or ACE inhibitor, compared to ~14 months for those receiving only a low dose bevacizumab [64].